|
51
|
Clinical |
抗癌藥品臨床評估考量重點指導原則(第二版)
|
2025-09-24 |
|
52
|
Product specific BE guideline |
Lidocaine Patch-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
53
|
Product specific BE guideline |
Drospirenone/Ethinyl Estradiol Tablets-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
54
|
Product specific BE guideline |
Sorafenib Tosylate Tablets-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
55
|
Product specific BE guideline |
Sunitinib Hard Capsules-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
56
|
Product specific BE guideline |
Temozolomide Capsules-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
57
|
Product specific BE guideline |
Ticagrelor Tablets-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
58
|
Product specific BE guideline |
Trientine Dihydrochloride Capsules-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
59
|
Product specific BE guideline |
Rivaroxaban Tablets-學名藥生體相等性試驗指導原則
|
2025-09-24 |
|
60
|
Clinical |
基因治療製劑臨床研發策略指導原則
|
2025-09-24 |
